SCHEMBL5202970

SCHEMBL5202970

N[C@@H]1CCC(=O)NC1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL444005 1.00
SCHEMBL528253 1.00
Hydrochloric Acid SCHEMBL33649 0.98 CRBN (0.44)
Hydrochloric Acid SCHEMBL19347669 0.98 CRBN (0.44)
Bromide SCHEMBL3546365 0.98 CRBN (0.44)
Hydrochloric Acid SCHEMBL22720839 0.98 CRBN (0.44)
Hydrochloric Acid SCHEMBL22720671 0.98 CRBN (0.44)
Bromide SCHEMBL3545017 0.98 CRBN (0.44)
Bromide SCHEMBL5203587 0.98 CRBN (0.44)
Hydrochloric Acid SCHEMBL283133 0.95 CRBN (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1353672-B1 SYNTHESIS OF 4-AMINO-THALIDOMIDE ENANTIOMERS CHILDRENS MEDICAL CENTER (US) 2007-10-03 EP claimed
US-20240199638-A1 GLUTARIMIDES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2024-06-20 US disclosed
CN-118108706-A Glutarimide C4医药公司 2024-05-31 CN disclosed
US-20240166647-A1 Cereblon Ligands THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2024-05-23 US disclosed
CN-111278815-B Glutarimide C4医药公司 2024-03-08 CN disclosed
WO-2024037527-A1 BTK DEGRADING COMPOUNDS BEIJING NEOX BIOTECH LIMITED (CN) 2024-02-22 WO disclosed
WO-2024015412-A1 TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2024-01-18 WO disclosed
US-11820781-B2 Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway NURIX THERAPEUTICS, INC. (US) 2023-11-21 US disclosed
US-11820720-B2 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deuteropiperidine-2,6-dione derivatives and compositions comprising and methods of using the same SALARIUS PHARMACEUTICALS, INC. (US) 2023-11-21 US disclosed
US-11820781-B2 Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway NURIX THERAPEUTICS, INC. (US) 2023-11-21 US disclosed
WO-2023283263-A1 CITRATE SALT, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THE SAME FOGHORN THERAPEUTICS INC. (US) 2023-01-12 WO disclosed
WO-2022187423-A1 CEREBLON LIGANDS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2022-09-09 WO disclosed
WO-2021231927-A1 ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2021-11-18 WO disclosed
US-20210198280-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY NURIX THERAPEUTICS, INC. 2021-07-01 US disclosed
WO-2021113557-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY NURIX THERAPEUTICS, INC. (US) 2021-06-10 WO disclosed
WO-2021105335-A1 PIPERIDINE-2, 6-DIONE DERIVATIVES WHICH BIND TO CEREBLON, AND METHODS OF USE THEREOF CAPTOR THERAPEUTICS S.A. (PL) 2021-06-03 WO disclosed
US-9913845-B2 3-(substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same DEUTERX, LLC (US) 2018-03-13 US disclosed
EP-3202460-A1 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME Celgene Corporation (US) 2017-08-09 EP disclosed
EP-2536706-B1 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CELGENE CORP (US) 2017-06-14 EP disclosed
WO-2004022536-A1 NEW HETEROCYCLIC AMIDE COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM GLENMARK PHARMACEUTICALS LIMITED (US) 2004-03-18 WO disclosed